Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RT023 in advanced malignant solid tumors
CTR20263318Phase 2Active
- Sponsor
- Shanghai Ruotuo Biotechnology
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RT023 in Nonhematologic neoplasms, sponsored by Shanghai Ruotuo Biotechnology. Started Sep 2026; status: active.
02
Drugs
RT023
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263318.